文献速递炎症性肠病

维得利珠单抗与乌司奴单抗在肿瘤坏死因子α抑制剂治疗失败的克罗恩病患者中疗效的客观比较

An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
PubMed 文献 · Am J Gastroenterol · 2022-04-13

这项多中心观察性回顾性队列研究纳入470例肿瘤坏死因子α抑制剂治疗失败的克罗恩病患者,比较维得利珠单抗与乌司奴单抗作为二线治疗的疗效。第26周两组临床结局相似;第52周维得利珠单抗组临床缓解率和无激素缓解率显著高于乌司奴单抗组,但客观缓解与客观缓解率两组相似,安全性相似。

要点

  • 第26周时两组临床结局相似。
  • 第52周维得利珠单抗组临床缓解率42.5% vs 乌司奴单抗组55.5%,P=0.01。
  • 第52周两组客观缓解与客观缓解率相似,安全性相似。

核心结论

  • 在肿瘤坏死因子α抑制剂治疗失败的克罗恩病患者中,乌司奴单抗与维得利珠单抗治疗26周后临床疗效相似。
  • 治疗1年时,维得利珠单抗与较高的临床缓解率相关。
  • 然而,在该时间点评估客观结局时,两组间未观察到差异。

研究设计与样本

  • 多中心观察性回顾性队列研究,采用倾向性评分加权和倾向性评分匹配。
  • 共纳入470例肿瘤坏死因子α抑制剂治疗失败的克罗恩病患者,其中乌司奴单抗组239例,维得利珠单抗组231例。
  • 评估第26周和第52周的临床应答、临床缓解及无激素缓解。
  • 通过内镜、磁共振/计算机断层扫描小肠造影和小肠超声中至少一种技术评估客观应答和客观缓解。

主要发现

  • 第26周时两组临床结局相似。
  • 第52周临床缓解率:乌司奴单抗组42.5% vs 维得利珠单抗组55.5%,P=0.01,维得利珠单抗组显著更高。
  • 第52周无激素缓解率:乌司奴单抗组40.6% vs 维得利珠单抗组51.1%,P=0.038,维得利珠单抗组显著更高。
  • 第52周客观应答率和客观缓解率两组相似。
  • 第26周临床应答可预测两组第52周无激素缓解;两组安全性特征相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The use of ustekinumab and vedolizumab as second-line therapies in patients with Crohn's disease (CD) in which tumour necrosis factor alpha inhibitors (TNFi) failed is still debated. The aim of this study was to compare, in a large multicenter observational retrospective cohort, the effectiveness of ustekinumab and vedolizumab as second-line therapies, as assessed by clinical and objective outcomes including endoscopy and gastrointestinal imaging. METHODS: Clinical response, remission, and steroid-free remission at weeks 26 and 52 were evaluated in a retrospective propensity score-weighted and propensity score-matched cohort of patients in which TNFi failed. Objective response and remission were evaluated by 1 or more techniques among endoscopy, magnetic resonance/computed tomography enteroclysis, and small bowel ultrasound. RESULTS: A total of 470 patients with CD (239 treated with ustekinumab and 231 treated with vedolizumab) were included in the study. At week 26, clinical outcomes were similar between the 2 groups. At week 52, clinical remission (ustekinumab 42.5% vs vedolizumab 55.5%, P = 0.01) and steroid-free remission (ustekinumab 40.6% vs vedolizumab 51.1%, P = 0.038) rates were significantly higher in vedolizumab-treated patients. Three hundred two patients (hundred thirty-five treated with ustekinumab and hundred sixty-seven treated with vedolizumab) had an objective evaluation of disease activity at baseline and week 52. At week 52, objective response and remission rates were similar between the 2 groups. Clinical response at week 26 predicted steroid-free remission at week 52 in both ustekinumab-treated and vedolizumab-treated patients. Safety profiles were similar between the 2 groups. DISCUSSION: In patients with CD in which TNFi failed, both ustekinumab and vedolizumab showed similar clinical effectiveness after 26 weeks of treatment. At 1 year, vedolizumab was associated with a higher rate of clinical remission when compared with ustekinumab. However, no difference was observed between the 2 groups when objective outcomes were investigated at this time point.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Onali S, Pugliese D, Caprioli FA, et al. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022. PMID: 35467558. doi:10.14309/ajg.0000000000001773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。